Xenon Pharmaceuticals Announces 2026 Annual Meeting of Shareholders: Key Details for Investors

Summary of Key Points

• Annual Meeting Date: June 2, 2026
• Record Date for Notice and Voting: April 7, 2026
• Beneficial Ownership Determination Date: April 7, 2026
• Securities Entitled to Vote: Common Shares
• Notice-and-Access Delivery: Both registered and non-registered investors will receive meeting materials via notice-and-access
• Issuer Mailing to Non-Objecting Beneficial Owners: No
• Issuer Will Pay for Objecting Beneficial Owner Material Distribution: Yes

Detailed Information for Shareholders

Xenon Pharmaceuticals Inc. has officially notified securities regulators and its investors of the upcoming Annual Meeting of Shareholders, which is scheduled for June 2, 2026. This meeting is a critical event for existing and prospective shareholders, as decisions made during annual meetings can directly impact the company’s strategic direction and, consequently, its share value.

The record date for notice and voting is set for April 7, 2026. This means that only shareholders of record as of this date will be eligible to receive notice of the meeting and vote on issues presented. Additionally, the same date applies for determining beneficial ownership, ensuring clarity on who is entitled to participate.

Common Shares are the only class of securities entitled to both notice and voting rights at this meeting. Investors holding common shares as of the record date should expect to receive all relevant materials concerning the meeting.

Notably, Xenon Pharmaceuticals is utilizing a notice-and-access system for disseminating meeting materials to both registered and non-registered shareholders. This approach, which provides electronic access to materials rather than physical mailings, is increasingly preferred for its efficiency and environmental benefits. Shareholders should ensure their contact information is up to date with their brokers or the company’s transfer agent to avoid missing these important communications.

Distribution to Non-Objecting Beneficial Owners (NOBOs): The company will not mail materials directly to NOBOs, which may require these shareholders to access documents through alternative channels.

Objecting Beneficial Owners (OBOs): Xenon Pharmaceuticals will bear the cost of distributing meeting materials to OBOs, ensuring all shareholders have access to the information they need to make informed voting decisions.

There are no notice-and-access stratification criteria specified, meaning all shareholders will receive the same method of communication, ensuring equal access to meeting details.

Potential Share Price Impact

While this notice primarily provides routine procedural information regarding the annual meeting, investors should note that annual meetings often include matters such as the election of directors, approval of auditors, and potential updates on corporate strategies. These topics can sometimes include price-sensitive information or proposals that could impact the company’s valuation and future performance.

Investors are encouraged to monitor further disclosures regarding the specific agenda for the June 2, 2026 meeting, as items to be voted on can influence shareholder sentiment and, by extension, the company’s share price.

The company’s continued use of notice-and-access demonstrates a commitment to cost efficiency and modern investor communications, which may be viewed positively from a corporate governance perspective.

Next Steps for Shareholders

• Mark June 2, 2026 in your calendar as the date of the Annual Meeting.
• Ensure that you are a shareholder of record as of April 7, 2026 to participate and vote at the meeting.
• Look out for notice-and-access instructions from Xenon Pharmaceuticals or your broker/transfer agent.
• Review all meeting materials carefully once available, as proposals and voting items will be disclosed closer to the meeting date.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should consult official company disclosures and their financial advisors before making investment decisions. The information is based solely on the contents of the provided document and does not account for other developments at Xenon Pharmaceuticals Inc. or in the broader market.

View Xenon Pharmaceuticals Inc. Historical chart here